The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
The ongoing discussion regarding insurer coverage for GLP-1 medications such as Ozempic and Wegovy has reignited a familiar debate concerning the origins of illness. Some argue these weight-loss drugs are shortcuts, while others emphasize the impact of socioeconomic factors on body weight.
A recent study has uncovered a potential connection between glucagon-like peptide-1 (GLP-1) receptor agonists and chronic cough in individuals managing type 2 diabetes. The research suggests that those using GLP-1 drugs were more prone to developing a persistent cough compared to those on alternative second-line treatments.
GLP-1 drugs are prescription medicines utilized to treat type 2 diabetes and aid weight loss under medical supervision. These medications work by imitating hormones responsible for controlling blood sugar and appetite. It is important to obtain them from regulated sources.
Ozempic, along with other weight loss medications, has demonstrated potential in mitigating health risks. However, lawsuits are emerging, alleging a connection between these drugs and vision loss. Patients are filing claims against the manufacturers.
New research reveals that medications like Ozempic are associated with considerable decreases in household food expenditures, both in grocery stores and restaurants. The study highlights how the adoption of GLP-1 drugs impacts daily food purchasing in real-world scenarios, showing a notable shift in consumer behavior.
Drug manufacturers are creating oral GLP-1 medications for obesity management. Injectable GLP-1 drugs like Ozempic have limitations, but pill versions offer a new option. One Wegovy pill is anticipated to receive FDA approval this year.
ShantaQuilette Carter-Williams shares her experience with GLP-1 medications after facing serious health issues. Her story highlights the transformative impact on her health, lifestyle, and relationships.
Semaglutide (Wegovy) is nearing PBS inclusion for adults with cardiovascular disease and obesity, following a PBAC recommendation. The recommendation identifies specific groups to prioritize for access to GLP-1 receptor agonist medicines.
In response to the increasing demand for GLP-1 weight-management solutions and the risks associated with unregulated online sales, FastMed has launched a program providing a secure and compliant channel for individuals seeking weight management assistance. The platform emphasizes the importance of medical supervision when using prescription weight-loss medications.
